[卫生技术评估：一种基于价值的医疗技术评估工具。细胞培养衍生四价流感疫苗Flucelvax Tetra 2.0的重新评估] - Suppr

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].

作者信息

Calabrò Giovanna Elisa, Boccalini Sara, Bechini Angela, Panatto Donatella, Domnich Alexander, Lai Piero Luigi, Amicizia Daniela, Rizzo Caterina, Pugliese Andrea, DI Pietro Maria Luisa, Zanella Beatrice, Parente Flavio, Trombetta Carlo Simone, Saraceno Giovanni, Sottile Sara, Abreha Fasika Molla, Giacchetta Irene, Properzi Sara, Santolini Giulia, D'Ambrosio Floriana, Maida Ada, Scardigno Anna, LA Gatta Emanuele, Petrella Luigi, Bonanni Paolo, DE Waure Chiara

机构信息

Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.

VIHTALI (Value In Health Technology and Academy for Leadership & Innovation), Spin-off dell'Università Cattolica del Sacro Cuore, Roma, Italia.

出版信息

J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec.

DOI:10.15167/2421-4248/jpmh2022.63.4s1

PMID:37034835

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10079375/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0940/10079375/d3587299f48c/jpmh-2022-04-S1-g006.jpg

相似文献

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].

J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec.

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax Tetra/Flucelvax Quadrivalent): A Review in the Prevention of Influenza.

Drugs. 2019 Aug;79(12):1337-1348. doi: 10.1007/s40265-019-01176-z.

Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.

Vaccine. 2023 Jan 9;41(2):304-314. doi: 10.1016/j.vaccine.2022.10.006. Epub 2022 Dec 13.

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.

Clin Infect Dis. 2023 Feb 8;76(3):e1168-e1176. doi: 10.1093/cid/ciac683.

Flucelvax (Optaflu) for seasonal influenza.

Expert Rev Vaccines. 2015 Jun;14(6):789-804. doi: 10.1586/14760584.2015.1039520.

Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.

Clin Infect Dis. 2021 Dec 6;73(11):1973-1981. doi: 10.1093/cid/ciab566.

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.

MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1.

A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.

Vaccine. 2020 Jul 14;38(33):5171-5177. doi: 10.1016/j.vaccine.2020.06.023. Epub 2020 Jun 21.

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.

Braz J Infect Dis. 2017 Jan-Feb;21(1):63-70. doi: 10.1016/j.bjid.2016.10.003. Epub 2016 Nov 29.

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax Tetra/Flucelvax Quadrivalent): A Review in the Prevention of Influenza.

Drugs. 2019 Dec;79(18):2009. doi: 10.1007/s40265-019-01237-3.

引用本文的文献

[Not Available].

J Prev Med Hyg. 2025 Apr 15;66(1 Suppl 2):E1-E56. doi: 10.15167/2421-4248/jpmh2025.66.1s2. eCollection 2025 Apr.

The Evolution of Annual Immunization Recommendations Against Influenza in Italy: The Path to Precision Vaccination.

Vaccines (Basel). 2025 Mar 27;13(4):356. doi: 10.3390/vaccines13040356.

Health Technology Assessment of Vaccines in Italy: History and Review of Applications.

Vaccines (Basel). 2024 Sep 24;12(10):1090. doi: 10.3390/vaccines12101090.

The economic and fiscal impact of incremental use of cell-based quadrivalent influenza vaccine for the prevention of seasonal influenza among healthcare workers in Italy.

Health Res Policy Syst. 2024 Mar 22;22(1):36. doi: 10.1186/s12961-024-01122-w.

Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine.

Hum Vaccin Immunother. 2023 Aug;19(2):2261689. doi: 10.1080/21645515.2023.2261689. Epub 2023 Oct 3.

本文引用的文献

Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.

Vaccine. 2022 May 11;40(22):2999-3008. doi: 10.1016/j.vaccine.2022.04.019. Epub 2022 Apr 19.

Seasonal influenza in children: Costs for the health system and society in Europe.

Influenza Other Respir Viruses. 2022 Sep;16(5):820-831. doi: 10.1111/irv.12991. Epub 2022 Apr 15.

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment.

Int J Environ Res Public Health. 2022 Mar 31;19(7):4166. doi: 10.3390/ijerph19074166.

Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis.

Vaccine. 2022 Apr 26;40(19):2679-2695. doi: 10.1016/j.vaccine.2022.03.041. Epub 2022 Mar 31.

Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.

EClinicalMedicine. 2022 Mar 25;46:101331. doi: 10.1016/j.eclinm.2022.101331. eCollection 2022 Apr.

The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.

Front Public Health. 2022 Mar 9;10:786662. doi: 10.3389/fpubh.2022.786662. eCollection 2022.

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey.

J Pers Med. 2022 Jan 20;12(2):139. doi: 10.3390/jpm12020139.

Systematic review of the efficacy, effectiveness and safety of MF59 adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.

Rev Med Virol. 2023 May;33(3):e2329. doi: 10.1002/rmv.2329. Epub 2022 Feb 10.

Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.

Rev Med Virol. 2023 May;33(3):e2330. doi: 10.1002/rmv.2330. Epub 2022 Feb 4.

Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.

Rev Med Virol. 2023 May;33(3):e2331. doi: 10.1002/rmv.2331. Epub 2022 Feb 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献